Clinical and metabolic phenotypes of Oxford Biobank subjects with variations in human flavin-containing monooxygenase 5 (FMO5)
Heterozygous coding variations in human FMO5 appeared to have some impact on the clinical phenotype of the females in this study but the natural variation in the levels of 2,3-butanediol was higher than any inter-group differences between women with heterozygous coding variations in human FMO5 and the women in the control group with wildtype FMO5.
Authors
- Matt J. Neville (ORCID: https://orcid.org/0000-0002-6004-5433)
- Jeremy R. Everett (ORCID: https://orcid.org/0000-0003-1550-4482)
- Christina Redfield (ORCID: https://orcid.org/0000-0001-7297-7708)
- Fredrik Karpe (ORCID: https://orcid.org/0000-0002-2751-1770)
- Adrien Le Guennec (ORCID: https://orcid.org/0000-0002-9770-9184)
Institutions
- King's College London (GB)
- University of Oxford (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Oxford BioMedica (United Kingdom) (GB)
- University of Greenwich (GB)
Publication Details
- Journal
- Metabolomics
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1007/s11306-025-02308-1
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- University of Southampton
- University of Oxford
- Engineering and Physical Sciences Research Council